Table 1.

Median OS and HRs for death by treatment (HD vs SD), according to subgroup

Subgroup	Standard dose (45 mg/m2 per day)			High dose (90 mg/m2 per day)			Fisher’s exact P	Log-rank P	Univariate		Multivariable*
	CR rate	Median OS (months) (no. of events/total)	4-year OS	CR rate	Median OS (months) (no. of events/total)	4-year OS			HR (95% CI)	Wald P	No. of events/total	HR (95% CI)	Wald P
All patients	59%	16.6 (246/330)	31%	71%	25.4 (207/327)	39%	.001	.001	0.74 (0.61, 0.89)	0.001	450/653	0.74 (0.61, 0.89)	.001
Age
<50 years	61%	20.7 (133/188)	35%	73%	44.7 (96/172)	48%	.02	.002	0.66 (0.50, 0.85)	0.002	228/359	0.67 (0.52, 0.88)	.004
≥50 years	56%	12.6 (113/142)	25%	68%	17.6 (111/155)	28%	.03	.12	0.81 (0.62, 1.06)	0.12	222/294	0.82 (0.63, 1.07)	.14
Cytogenetic
Favorable	84%	39.4 (24/38)	46%	80%	NR (19/51)	64%	.78	.02	0.51 (0.28, 0.93)	0.03	43/89	0.44 (0.24, 0.82)	.01
Intermediate	56%	20.1 (101/141)	35%	77%	33.5 (71/127)	45%	.0003	.01	0.68 (0.50, 0.92)	0.01	172/267	0.75 (0.55,1.03)	.08
Indeterminate	62%	14.3 (66/91)	29%	67%	21.3 (62/85)	29%	.53	.47	0.88 (0.62, 1.24)	0.47	127/175	0.89 (0.63, 1.27)	.53
Unfavorable	44%	10.2 (54/59)	14%	57%	10.6 (54/63)	19%	.20	.22	0.79 (0.54, 1.16)	0.23	108/122	0.66 (0.44, 0.98)	.04
Gene mutation
NPM1	60%	16.9 (50/65)	29%	89%	75.9 (31/65)	52%	.0002	.002	0.50 (0.32, 0.78)	0.002	81/130	0.51 (0.32, 0.81)	.005
FLT3-ITD	48%	10.1 (74/83)	17%	70%	15.2 (44/64)	28%	.008	.009	0.61 (0.42, 0.89)	0.009	117/146	0.50 (0.32, 0.77)	.002
DNMT3A	61%	14.1 (55/61)	13%	79%	16.5 (40/58)	33%	.03	.02	0.62 (0.41, 0.94)	0.02	95/118	0.67 (0.42, 1.05)	.08
MLL-PTD	56%	16.2 (16/16)	6%	60%	20.6 (10/15)	33%	1.00	.056	0.46 (0.21, 1.04)	0.06	26/30	0.60 (0.24, 1.54)	.29

NR, not reached.

^*Adjusted for sex, age, hemoglobin level, leukocyte count, platelet count, and cytogenetics.